$5.77
Live
0.0%
Downside
Day's Volatility :5.56%
Upside
5.56%
49.39%
Downside
52 Weeks Volatility :64.82%
Upside
30.48%
Period | Airsculpt Technologies | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 25.11% | 3.6% | 0.0% |
6 Months | 4.77% | 10.2% | 0.0% |
1 Year | -15.04% | 19.6% | 0.0% |
3 Years | -62.68% | 16.8% | -23.0% |
Market Capitalization | 334.6M |
Book Value | $1.48 |
Earnings Per Share (EPS) | -0.06 |
Wall Street Target Price | 3.92 |
Profit Margin | -1.77% |
Operating Margin TTM | -9.77% |
Return On Assets TTM | 2.45% |
Return On Equity TTM | -4.11% |
Revenue TTM | 193.0M |
Revenue Per Share TTM | 3.37 |
Quarterly Revenue Growth YOY | -8.4% |
Gross Profit TTM | 110.5M |
EBITDA | 19.5M |
Diluted Eps TTM | -0.06 |
Quarterly Earnings Growth YOY | 2.0 |
EPS Estimate Current Year | -0.05 |
EPS Estimate Next Year | -0.03 |
EPS Estimate Current Quarter | 0.04 |
EPS Estimate Next Quarter | 0.03 |
What analysts predicted
Downside of 32.06%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 41.2M | - |
Net Income | -5.1M | - |
Net Profit Margin | -12.34% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 62.8M | ↑ 52.21% |
Net Income | 5.8M | ↓ 213.03% |
Net Profit Margin | 9.16% | ↑ 21.5% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 133.3M | ↑ 112.4% |
Net Income | 10.6M | ↑ 83.5% |
Net Profit Margin | 7.91% | ↓ 1.25% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 168.8M | ↑ 26.61% |
Net Income | -14.7M | ↓ 239.12% |
Net Profit Margin | -8.7% | ↓ 16.61% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 195.9M | ↑ 16.07% |
Net Income | -4.5M | ↓ 69.49% |
Net Profit Margin | -2.29% | ↑ 6.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 45.8M | ↑ 12.55% |
Net Income | -14.0K | ↓ 99.81% |
Net Profit Margin | -0.03% | ↑ 17.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 55.7M | ↑ 21.59% |
Net Income | 1.8M | ↓ 12785.71% |
Net Profit Margin | 3.19% | ↑ 3.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.8M | ↓ 16.0% |
Net Income | -1.7M | ↓ 193.86% |
Net Profit Margin | -3.56% | ↓ 6.75% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 47.6M | ↑ 1.74% |
Net Income | -4.6M | ↑ 174.39% |
Net Profit Margin | -9.61% | ↓ 6.05% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 47.6M | ↑ 0.03% |
Net Income | 6.0M | ↓ 231.81% |
Net Profit Margin | 12.66% | ↑ 22.27% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 51.0M | ↑ 7.11% |
Net Income | -3.2M | ↓ 153.18% |
Net Profit Margin | -6.29% | ↓ 18.95% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 171.5M | - |
Total Liabilities | 51.1M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 179.6M | ↑ 4.73% |
Total Liabilities | 55.9M | ↑ 9.44% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 200.6M | ↑ 11.66% |
Total Liabilities | 117.0M | ↑ 109.22% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 200.8M | ↑ 0.1% |
Total Liabilities | 130.0M | ↑ 11.08% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 213.6M | ↑ 6.37% |
Total Liabilities | 129.6M | ↓ 0.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 209.5M | ↑ 4.36% |
Total Liabilities | 134.3M | ↑ 3.31% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 217.3M | ↑ 3.71% |
Total Liabilities | 135.8M | ↑ 1.13% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 204.1M | ↓ 6.06% |
Total Liabilities | 119.9M | ↓ 11.69% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 213.6M | ↑ 4.62% |
Total Liabilities | 129.6M | ↑ 8.03% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 202.7M | ↓ 5.08% |
Total Liabilities | 119.2M | ↓ 7.99% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 210.1M | ↑ 3.65% |
Total Liabilities | 125.1M | ↑ 4.94% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.9M | - |
Investing Cash Flow | -4.4M | - |
Financing Cash Flow | -783.0K | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.0M | ↑ 182.64% |
Investing Cash Flow | -3.7M | ↓ 16.9% |
Financing Cash Flow | -5.0M | ↑ 540.74% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 26.6M | ↑ 90.82% |
Investing Cash Flow | -7.1M | ↑ 92.9% |
Financing Cash Flow | -4.5M | ↓ 9.33% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 24.4M | ↓ 8.21% |
Investing Cash Flow | -12.9M | ↑ 81.58% |
Financing Cash Flow | -27.3M | ↑ 499.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.2M | ↓ 6.34% |
Investing Cash Flow | -3.8M | ↑ 73.8% |
Financing Cash Flow | -737.0K | ↓ 69.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 12.2M | ↑ 96.75% |
Investing Cash Flow | -2.2M | ↓ 43.36% |
Financing Cash Flow | -579.0K | ↓ 21.44% |
Sell
Neutral
Buy
Airsculpt Technologies is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Airsculpt Technologies | 8.81% | 4.77% | -15.04% | -62.68% | -62.68% |
Fresenius Medical Care Ag | 1.13% | -0.24% | 18.22% | -43.13% | -40.13% |
Hca Holdings, Inc. | 2.43% | 33.91% | 72.47% | 59.82% | 236.17% |
Tenet Healthcare Corp. | -2.48% | 72.77% | 199.8% | 132.6% | 569.4% |
Universal Health Services Inc. | -1.63% | 46.88% | 89.37% | 72.31% | 62.86% |
Davita Healthcare Partners Inc. | 0.24% | 22.22% | 105.36% | 40.34% | 176.12% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Airsculpt Technologies | 193.0 | NA | NA | -0.05 | -0.04 | 0.02 | NA | 1.48 |
Fresenius Medical Care Ag | 20.24 | 20.24 | 0.41 | 2.52 | 0.05 | 0.03 | 0.03 | 47.48 |
Hca Holdings, Inc. | 19.51 | 19.51 | 1.23 | 22.62 | 0.74 | 0.11 | 0.01 | -6.17 |
Tenet Healthcare Corp. | 5.89 | 5.89 | 0.83 | 10.57 | 0.55 | 0.07 | NA | 36.27 |
Universal Health Services Inc. | 17.4 | 17.4 | 1.87 | 15.93 | 0.15 | 0.06 | 0.0 | 97.21 |
Davita Healthcare Partners Inc. | 17.05 | 17.05 | 1.53 | 9.8 | 0.45 | 0.07 | NA | 7.44 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Airsculpt Technologies | Buy | $334.6M | -62.68% | 193.0 | -1.77% |
Fresenius Medical Care Ag | Hold | $11.8B | -40.13% | 20.24 | 2.73% |
Hca Holdings, Inc. | Buy | $107.2B | 236.17% | 19.51 | 8.4% |
Tenet Healthcare Corp. | Buy | $15.5B | 569.4% | 5.89 | 13.18% |
Universal Health Services Inc. | Hold | $15.8B | 62.86% | 17.4 | 6.22% |
Davita Healthcare Partners Inc. | Hold | $13.4B | 176.12% | 17.05 | 6.86% |
Insights on Airsculpt Technologies
Revenue is up for the last 4 quarters, 46.79M → 51.00M (in $), with an average increase of 2.8% per quarter
Netprofit is down for the last 2 quarters, 6.02M → -3.20M (in $), with an average decrease of 153.2% per quarter
In the last 1 year, Tenet Healthcare Corp. has given 200.3% return, outperforming this stock by 213.2%
Vesey Street Capital Partners, L.L.C.
SW Investment Management LLC
BlackRock Inc
Vanguard Group Inc
Balyasny Asset Management LLC
Geode Capital Management, LLC
at elite body sculpture we focus on body contouring. using our minimally invasive and patented airsculpt® technology, our procedures are geared to make healing faster with less bruising and less trauma to the area being treated. our commitment is to provide the very best possible results for each patient, using the most up to date and advanced technology.
Organization | Airsculpt Technologies |
Employees | 346 |
CEO | Dr. Aaron J. Rollins M.D. |
Industry | Healthcare |